Search

everythinglearnresearchcommunity

for

Search:↓

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Blocking specific proteins can help remove aging cells and might treat age-related diseases and promote hair growth.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Nilotinib can cause skin issues like red bumps and hair loss.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.